Q&A with Babu Padmanabhan, STEER Engineering - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Babu Padmanabhan, STEER Engineering
A Q&A with Babu Padmanabhan, Managing Director and Chief Knowledge Officer of STEER Engineering, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 8, pp. 71



Q&A with
Babu Padmanabhan, Managing Director and Chief Knowledge Officer of STEER Engineering

PharmTech:
How has the increasing focus on biopharmaceuticals affected your business?

Padmanabhan:
Our organization supports the bio/pharmaceutical industry by improving the effectiveness of the oral, skin, and intramuscular drug-delivery systems. We build the tools for engineering sustained and controlled release of drugs, enhanced bioavailability, drug-eluting stents, and implant-based, innovative drug-release systems. These methods are recent developments and have potential in both small-molecule drugs and biopharmaceuticals.

PharmTech:
How is your company responding to regulators' intensifying emphasis on inspections and product quality?

Padmanabhan:
Because we build tools for developing and manufacturing drug products, our equipment is built with full range of instrumentation and analytical systems that are compliant with current global regulatory requirements. We provide support in meeting the requirements of the design-, installation-, operational-, and performance-qualification protocols of various companies. Because of our exposure to many such protocols, our support to companies move them towards a better set of requirements (i.e., exceeding current requirements and preparing for the future).

PharmTech:
Do you see a new industry trend emerging?

Padmanabhan:
Continuous manufacturing is gaining significant attention among the pharmaceutical industry. Life-cycle management of existing drugs has been one of the current areas of focus. There is growing interest in equipment that supports the manufacturing of potent compounds with containment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here